Louisiana Misoprostol Controlled Substance Law
Analysis based on 8 articles · First reported Jul 23, 2026 · Last updated Aug 03, 2026
The law increases operational burdens and liability risks for healthcare providers in United States — Louisiana, potentially raising costs and reducing access to essential medications. Pharmaceutical companies may face reputational and regulatory scrutiny, while the broader healthcare sector could see increased litigation and policy uncertainty.
In 2024, United States — Louisiana passed a law reclassifying misoprostol and mifepristone as controlled substances, primarily due to their use in medication abortions. This has forced hospitals to store misoprostol in secure rooms, delaying access during postpartum hemorrhages. Physicians report worsened hemorrhage rates and increased patient risk. The law has also led to pharmacy refusals and reduced access to these drugs for other medical uses. Similar legislation has been introduced in at least nine other states, but none have reclassified the drugs. The United States — New Orleans Health Department has called for repeal, and United States — Louisiana has sued the FDA over telehealth abortion restrictions, a case pending before the United States — Supreme Court of the United States.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard